In the United States, annual sales generated by the branded product and a generic competitor (with which Acrux’s generic will compete) exceeded USD$23 million and 47,000 packs based on sales reported by IQVIA1.
yep huge market but growing - so lets see how they go about taking market share from the branded product and the generic competitor - advertising budget/commission structure for this pls.
Add to My Watchlist
What is My Watchlist?
 (20min delay)
|
|||||
|
Last
1.7¢ |
Change
-0.001(5.56%) |
Mkt cap ! $6.931M | |||
| Open | High | Low | Value | Volume |
| 1.8¢ | 1.9¢ | 1.7¢ | $8.809K | 495.6K |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 5 | 266679 | 1.7¢ |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| 1.8¢ | 252359 | 2 |
View Market Depth
| Last trade - 14.49pm 24/06/2025 (20 minute delay) ? |
| ACR (ASX) Chart |